As more of these techniques are incorporated into clinical practice and larger data sets become available, further studies will be possible to test whether a combination of vascular normalization and immunotherapy could prevent the onset of resistance in HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.